176 related articles for article (PubMed ID: 2117797)
1. OKT3 in severe early rejection: predictors for reversal in renal transplant recipients.
Sumrani N; Delaney V; Rajpoot D; Tejani A; Butt K; Hong J
Transplant Proc; 1990 Aug; 22(4):1750-2. PubMed ID: 2117797
[No Abstract] [Full Text] [Related]
2. Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3).
Prieto C; Rodriguez-Paternina E; Andrés A; Morales JM; Farias J; Montoyo C; Regueiro JR; Rodicio JL
Transplant Proc; 1990 Aug; 22(4):1753-4. PubMed ID: 2117798
[No Abstract] [Full Text] [Related]
3. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
Chiu A; Landsberg D; Cameron EC; Manson AD; Shackleton C
Transplant Proc; 1991 Feb; 23(1 Pt 2):1039-40. PubMed ID: 1899146
[No Abstract] [Full Text] [Related]
4. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period.
Hesse UJ; Wienand P; Baldamus C; Arns W
Transplant Proc; 1990 Oct; 22(5):2273-4. PubMed ID: 2120814
[No Abstract] [Full Text] [Related]
5. Immunologic monitoring in OKT3-treated kidney graft recipients.
Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
[No Abstract] [Full Text] [Related]
6. Induction immunosuppression with OKT3 monoclonal antibody in cardiac transplant recipients.
Pulpón LA; Domínguez P; Cháfer M; Segovia J; Crespo MG; Pradas G; Burgos R; Figuera D
Transplant Proc; 1990 Oct; 22(5):2319. PubMed ID: 2120816
[No Abstract] [Full Text] [Related]
7. Use of OKT3 in kidney, pancreas, and liver transplantation.
D'Alessandro AM; Pirsch JD; Melzer JS; Sollinger HW; Kalayoglu M; Reed A; Knechtle SJ; Belzer FO
Transplant Proc; 1990 Aug; 22(4):1748-9. PubMed ID: 2117796
[No Abstract] [Full Text] [Related]
8. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
9. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
Light JA; Khawand N; Aquino A; Ali A; Korb S
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients.
Hanto DW; Jendrisak MD; McCullough CS; So SK; Marsh JW; Rush T; Michalski S; Phelan D; Mohanakumar T
Transplant Proc; 1991 Feb; 23(1 Pt 2):1050-1. PubMed ID: 1899150
[No Abstract] [Full Text] [Related]
11. Renal transplantation at the Washington Hospital Center: experience with OKT3 and Minnesota antilymphoblast globulin for induction of immunosuppression.
Jonsson J; Light JA; Korb SM
Clin Transpl; 1990; ():275-88. PubMed ID: 2129409
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
13. Acute pulmonary insufficiency due to OKT3 therapy.
Büsing M; Mellert J; Greger B; Hopt UT
Transplant Proc; 1990 Aug; 22(4):1779-81. PubMed ID: 2117808
[No Abstract] [Full Text] [Related]
14. Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation.
Welter HF; Illner WD; Schleibner S; Abendroth D; Hancke E; Groh J; Land W
Transplant Proc; 1990 Oct; 22(5):2272. PubMed ID: 2120813
[No Abstract] [Full Text] [Related]
15. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
16. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
[No Abstract] [Full Text] [Related]
17. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
18. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
Shield CF; Hughes JD
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
[TBL] [Abstract][Full Text] [Related]
19. Renal transplantation with cyclosporine in the elderly population.
Velez RL; Brinker KR; Vergne-Marini PJ; Nesser DA; Long DL; Trevino G; Dickerman RM; Helfrich GB
Transplant Proc; 1991 Apr; 23(2):1749-52. PubMed ID: 1905073
[No Abstract] [Full Text] [Related]
20. Transfusion effect still present with quadruple immunosuppression in recipients of renal transplants.
Yang HC; Weaver AS; Gifford RR
Transplant Proc; 1991 Feb; 23(1 Pt 2):1247-8. PubMed ID: 1899159
[No Abstract] [Full Text] [Related]
[Next] [New Search]
